Synthetic Cannabis and Bath Salts Went Undetected in Standard Drug Screens for Patient on Opioid Treatment | Research

The takeaway

A man on buprenorphine/naloxone treatment for opioid dependence presented with sedation, agitation, and paranoia after using K2, but standard drug testing (ELISA) failed to detect the synthetic cannabinoids and cathinones, which were only identified by advanced testing (GC-MS).

Addiction treatment providers and patients in medication-assisted treatment programs

Standard drug tests failed to detect

What the researchers found

The patient was unknowingly consuming synthetic cannabinoids and cathinones in a K2 blend while on buprenorphine/naloxone treatment. Standard ELISA drug testing failed to detect these substances. Only gas chromatography-mass spectrometry (GC-MS) identified them. The patient was unaware of the harmful constituents in the K2 product he was using.

Why it matters

Patients in opioid treatment programs may use synthetic drugs that evade routine monitoring, putting them at risk for dangerous interactions and treatment failure. Standard drug screens provide false reassurance when they cannot detect these substances.

The numbers in context

1 patient; 6 months into buprenorphine/naloxone treatment; ELISA negative; GC-MS positive for synthetic cannabinoids and cathinones; patient unaware of K2 blend contents

How the study worked

Single case report of a male in his thirties on buprenorphine/naloxone treatment who presented with sedation, agitation, and paranoia after six months of stable treatment. Standard and advanced toxicology testing performed.

What this study cannot tell us

Single case report cannot establish frequency of this problem. The specific synthetic compounds were not named. Interaction between synthetic cannabinoids/cathinones and buprenorphine/naloxone was not characterized. Cannot determine whether the synthetic drugs affected treatment efficacy.

How to read the evidence

Single case report highlighting a clinical diagnostic challenge

When this study was published

2023 study

The bigger picture

As synthetic drugs constantly evolve to evade detection, addiction treatment programs face an arms race. This case highlights the need for updated testing protocols and patient education about the dangers of novel synthetic substances.

Questions still open

How common is undetected synthetic drug use among opioid treatment patients? Should addiction programs routinely use GC-MS testing? Could synthetic cannabinoids interfere with buprenorphine efficacy?

Common questions

Can standard drug tests detect synthetic cannabis?

Not reliably. In this case, standard ELISA testing missed synthetic cannabinoids and cathinones completely. Only advanced testing (GC-MS) identified the substances, which is not routinely available.

Is it dangerous to use K2/Spice while on buprenorphine?

Yes. This patient developed sedation, agitation, and paranoia. Synthetic cannabinoids are unpredictable on their own, and their interactions with opioid treatment medications are poorly understood.

Read the original research

Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report.

Cureus, 15(11), e48386

View on PubMed ↗Publisher’s paper ↗

Citation

Awasthi, Harshal. (2023). Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report.. Cureus, 15(11), e48386. https://doi.org/10.7759/cureus.48386